A study to investigate if the success rates of fertility treatments for women with endometriosis is improved by taking the oral contraceptive pill for 8 weeks before treatment starts.

• Conditions: Sub-infertility due to endometriosis; MedDRA version: 14.1Level: LLTClassification code 10016402Term: Female infertility of pituitary-hypothalamic originSystem Organ Class: 100000004872; Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

• Registration Number: EUCTR2012-004954-27-GB
• Lead Sponsor: Clinical Trials and Research Governance, University of Oxford

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-11-30
• Last Update Posted: 10 March 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

• Participant is willing and able to give informed consent for participation in the study. • Female aged 18 to 39 years old. • Intending to undergo treatment with a first, second or third cycle of IVF or IVF-ICSI. • Diagnosed with any degree of endometriosis. • Participants must meet World Health Organisation Group 1 or 2 eligibility requirements for Combined Oral Contraceptive use.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 100
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

• The participant does not understand the English language, or has special communication needs. This is because it is impractical to provide, for this small scale study, information sheets and consent forms in other languages except English. • The patient has already undergone 3 or more IVF or IVF-ICSI cycles. • Patients who are already taking any medication to treat endometriosis such as progestins, OCP, GnRH agonists, danazol, mirena, etc. or who have done so within the last 3 months. • Participants who do not meet World Health Organisation Group 1 or 2 eligibility requirements for Combined Oral Contraceptive use.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified